(The following press release from Bayer was received by e-mail. It was not
confirmed by the sender.)
Dr. Jörg Reinhardt to leave Bayer HealthCare
Leverkusen, January 23, 2013 - Dr. Jörg Reinhardt (56), Chairman of the
Board of Management of Bayer HealthCare AG and a member of the Bayer AG
Executive Council, will not renew his contract when it expires in summer
2013. Instead he intends to stand for election as new Director of Swiss
healthcare company Novartis AG and designated non-executive Chairman of the
Board at its annual general meeting to be held at the end of February with
a view to assuming that office on August 1, 2013. Reinhardt will end his
active service with Bayer effective February 28, 2013.
Bayer AG Management Board member Prof. Wolfgang Plischke (61), whose
responsibilities currently include Technology, Innovation and
Sustainability, will take over the function of Chairman at Bayer HealthCare
in addition to his existing duties until a successor is appointed. Prior to
his appointment to the Bayer AG Board of Management on March 1, 2006,
Plischke had worked in the health care field for 25 years, latterly as
General Manager of what was then the Pharmaceuticals Business Group.
"With his experience and his commitment, Jörg has played a major part in
the very positive development of Bayer HealthCare in recent years," said
Bayer CEO Dr. Marijn Dekkers. "However, we accept his decision to continue
his career in his adopted country of Switzerland and wish him all the best
for the future."
Jörg Reinhardt has been Chairman of the Board of Management of Bayer
HealthCare AG since August 15, 2010. Born on March 11, 1956 in Homburg in
the German state of Saarland, Reinhardt studied pharmaceutical sciences at
Saarland University in Saarbrücken. After obtaining his doctorate in 1981,
he started his career with Sandoz, which became part of Novartis in 1996,
holding various managerial positions of increasing responsibility,
including Global Head of Pharmaceutical Development and CEO of the Vaccines
& Diagnostics Division. In 2008 he became Chief Operating Officer (COO) of
the Novartis group.
In April 2012, Reinhardt was appointed to the Board of Directors of Lonza
Group AG, Basel, Switzerland. Lonza is a global company that provides
products and services for the life sciences industry. Reinhardt is also a
member of the Council of the International Federation of Pharmaceutical
Manufacturers and Associations (IFPMA).
He is married and has two adult children.
Find more information at http://www.bayer.com.
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. These factors include those discussed in Bayer’s public reports
which are available on the Bayer website at http://www.bayer.com. The
company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.
Günter Forneck, Tel. +49 214 30-50446
Christian Hartel, Tel. +49 214 30-47686
This press release is available here:
Yours BayNews Editorial Team
51368 Leverkusen, Germany
Further news releases you can find here: http://www.press.bayer.com
To ensure receipt, please add email@example.com to your
address book or list of trusted senders.
© Bayer AG, 51368 Leverkusen, Germany
All rights reserved. The entire contents, including images, graphics,
animations etc., of this e-mail and the server http://www.press.bayer.com
Board of Management: Marijn Dekkers, Chairman of the Board | Werner
Baumann, Wolfgang Plischke, Richard Pott
Chairman of the Supervisory Board: Werner Wenning
Registered Office: Leverkusen | Local Court Cologne, HRB 48248
Press spacebar to pause and continue. Press esc to stop.